AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, D. J.
Right arrow Articles by Potvin, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, D. J.
Right arrow Articles by Potvin, J. H.
Agricola
Right arrow Articles by Goldstein, D. J.
Right arrow Articles by Potvin, J. H.

American Journal of Clinical Nutrition, Vol 60, 647-657, Copyright © 1994 by The American Society for Clinical Nutrition, Inc

REVIEW ARTICLES

Long-term weight loss: the effect of pharmacologic agents

DJ Goldstein and JH Potvin
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.

We reviewed 20 English-language weight-reduction studies, reported between 1967 and March 1993, of the effect of > or = 6 mo of pharmacologic therapy on weight loss and its maintenance to determine the clinical benefits of extended treatment, propose treatment guidelines, and identify future research needs. Pharmacologic agents included phentermine, mazindol, fenfluramine, dexfenfluramine, and fluoxetine. Study designs varied with respect to blinding, use of a single agent vs a combination, dosing, length of therapy, patient selection, adjunctive therapy, and visit frequency. At endpoint, weight loss varied from study to study but a plateauing of weight loss or weight regain was observed after approximately 6 mo. The benefits of extended treatment appear to outweigh the risks for those patients who are unable to lose sufficient weight without pharmacologic therapy but who maintain adequate weight loss with long-term pharmacologic therapy. Future studies should define and evaluate pharmacologically responsive and unresponsive subgroups.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
L. Aronne, K. Fujioka, V. Aroda, K. Chen, A. Halseth, N. C. Kesty, C. Burns, C. W. Lush, and C. Weyer
Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2977 - 2983.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
E. Colman
Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants
Ann Intern Med, September 6, 2005; 143(5): 380 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. L. Norris, X. Zhang, A. Avenell, E. Gregg, C. H. Schmid, C. Kim, and J. Lau
Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus: A Meta-analysis
Arch Intern Med, July 12, 2004; 164(13): 1395 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. A. Caccitolo, H. M. Connolly, D. S. Rubenson, T. A. Orszulak, and H. V. Schaff
Operation for anorexigen-associated valvular heart disease
J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 656 - 664.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
D. A. Anderson and T. A. Wadden
Treating the Obese Patient: Suggestions for Primary Care Practice
Arch Fam Med, March 1, 1999; 8(2): 156 - 167.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by The American Society for Nutrition